Supplementary Figure 1.docx (44.88 kB)

Supplementary Figure 1. Burden of Illness & Outcomes in 2nd Line Large B-Cell Lymphoma Treatment: Real-world Analysis of Medicare Beneficiaries

figure

posted on 20.10.2021, 08:18 by Karl M. Kilgore, Iman Mohammadi, Anny C. Wong, Julia Thornton Snider, Paul Cheng, Amy Schroeder, Anik R. Patel

Supplementary Figure 1. Overall Survival, Relative to Start of 2nd LOT, ASCT-Intended, Stratified by Time-to-Relapse

Funding

Kite, A Gilead Company, Santa Monica, CA

History

Usage metrics

Read the peer-reviewed publication

Burden of Illness & Outcomes in 2nd Line Large B-Cell Lymphoma Treatment: Real-world Analysis of Medicare Beneficiaries

Future Oncology

Categories

Cancer therapy (excl. chemotherapy and radiation therapy)

Keywords

Economic burden Medicare large B-cell lymphoma line of therapy stem-cell transplant treatment patterns Cancer Therapy (excl. Chemotherapy and Radiation Therapy)

Licence

CC BY-NC-ND 4.0

Exports